Adriamycin, BCNU plus cyclophosphamide (ABC) in advanced carcinoma of the head and neck.
Forty-four patients with advanced carcinoma of the head and neck were treated with cyclophosphamide, 400 mg/m2 plus BCNU, 100 mg/m2 day 1 followed by adriamycin 40 mg/m2 day 2, with therapy repeated every 4 weeks. Of 31 evaluable patients, there were 1 complete response, and 10 partial responses (35%). Four of 8 patients without prior chemotherapy had complete or partial responses, as did 7 of 23 patients who had received prior chemotherapy. The mean survival for patients with partial responses was 8.8 months, and for patients with stable disease was 7.8 months. The mean time to progression for patients with partial responses was 5.4 months, and for patients with stable disease was 3.2 months. Granulocytopenia was the dose limiting toxicity, and patients with increasing degrees of myelosuppression appeared to have higher quality responses and longer survival. The ABC treatment program is useful in the palliative management of patients with advanced carcinoma of the head and neck.
D000970:Antineoplastic Agents / Q000633:toxicity; D001853:Bone Marrow / Q000187:drug effects; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002330:Carmustine / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous
D000970:Antineoplastic Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D002330:Carmustine